CEACAM7 Antibody (BAC2): sc-59946

CEACAM7 Antibody (BAC2) is a mouse monoclonal IgG1 kappa light chain antibody that detects CEACAM7 protein of human origin by immunofluorescence (IF) and flow cytometry (FCM). Anti-CEACAM7 antibody (BAC2) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. CEACAM7, also known as carcinoembryonic antigen gene-family member 2 (CGM2), is a member of the carcinoembryonic antigen (CEA) family, which is crucial in cancer diagnostics as a tumor marker in serum immunoassays for carcinoma. CEACAM7 is primarily located on the apical surface of highly differentiated epithelial cells in the colorectal mucosa and isolated ductal epithelial cells in the pancreas, highlighting CEACAM7′s significance in maintaining epithelial integrity and function. CEACAM7 expression is notably downregulated in colorectal cancers, indicating CEACAM7′s potential role in tumorigenesis and suggesting involvement in the regulation of cell adhesion and signaling pathways critical for normal cellular function. Additionally, CEACAM7 interacts with CD66a, a biliary glycoprotein, which may further elucidate CEACAM7′s role in epithelial-microbial interactions and the immune response.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CEACAM7 Antibody (BAC2) References:

1. Four carcinoembryonic antigen subfamily members, CEA, NCA, BGP and CGM2, selectively expressed in the normal human colonic epithelium, are integral components of the fuzzy coat.  |  Frängsmyr, L., et al. 1999. Tumour Biol. 20: 277-92. PMID: 10436421
2. Carcinoembryonic antigen family members CEACAM6 and CEACAM7 are differentially expressed in normal tissues and oppositely deregulated in hyperplastic colorectal polyps and early adenomas.  |  Schölzel, S., et al. 2000. Am J Pathol. 156: 595-605. PMID: 10666389
3. Redefined nomenclature for members of the carcinoembryonic antigen family.  |  Beauchemin, N., et al. 1999. Exp Cell Res. 252: 243-9. PMID: 11501563
4. Long-term prognostic value of detection of circulating colorectal cancer cells using CGM2 reverse transcriptase-polymerase chain reaction assay.  |  Douard, R., et al. 2006. Surgery. 139: 556-62. PMID: 16627067
5. CEACAM-7: a predictive marker for rectal cancer recurrence.  |  Messick, CA., et al. 2010. Surgery. 147: 713-9. PMID: 20004437
6. Dynamic expression of CEACAM7 in precursor lesions of gastric carcinoma and its prognostic value in combination with CEA.  |  Zhou, J., et al. 2011. World J Surg Oncol. 9: 172. PMID: 22195770
7. CEACAM7 Is an Effective Target for CAR T-cell Therapy of Pancreatic Ductal Adenocarcinoma.  |  Raj, D., et al. 2021. Clin Cancer Res. 27: 1538-1552. PMID: 33479048
8. CEACAM7 polymorphisms predict genetic predisposition to mortality in post-surgical septic shock patients.  |  Pérez-García, F., et al. 2022. J Microbiol Immunol Infect. 55: 540-544. PMID: 34657826
9. CEACAM7 expression contributes to early events of pancreatic cancer.  |  Dhasmana, A., et al. 2024. J Adv Res. 55: 61-72. PMID: 36828119
10. CGM2, a member of the carcinoembryonic antigen gene family is down-regulated in colorectal carcinomas.  |  Thompson, J., et al. 1994. J Biol Chem. 269: 32924-31. PMID: 7806520
11. Dysregulation of carcinoembryonic antigen group members CGM2, CD66a (biliary glycoprotein), and nonspecific cross-reacting antigen in colorectal carcinomas. Comparative analysis by northern blot and in situ hybridization.  |  Nollau, P., et al. 1997. Am J Pathol. 151: 521-30. PMID: 9250164
12. Expression of four CEA family antigens (CEA, NCA, BGP and CGM2) in normal and cancerous gastric epithelial cells: up-regulation of BGP and CGM2 in carcinomas.  |  Kinugasa, T., et al. 1998. Int J Cancer. 76: 148-53. PMID: 9533775

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-CEACAM7 Antibody (BAC2) has 2 citations in a variety of scientific publications.

Primary antibodies like Anti-CEACAM7 Antibody (BAC2) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

CEACAM7 Antibody (BAC2) Specifications

Alternate Product Name: CEACAM7

Product Clone Name: BAC2

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids:

Epitope Target: CEACAM7

Epitope Species: human

Product Reactivity/Detection: CEACAM7

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: IF, FCM

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 2 citations in various scientific publications

Available Conjugates/Forms for CEACAM7 Antibody (BAC2): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin

The preferred pan CEA antibody is pan CEA Antibody (H-8): sc-48364.